Publications by authors named "Lilia M Correa-Selm"
Bevacizumab is a monoclonal antibody that exerts its antitumor activity by inhibiting vascular endothelial growth factor. Consequently, it suppresses endothelial cell proliferation, vascular permeability, and angiogenesis. This inhibitory effect contributes to tumour size reduction but causes wound-healing delay, specifically during the proliferative phase, in patients receiving bevacizumab.
View Article and Find Full Text PDFArticle Synopsis
- Melanocytes are not just found in the skin; they also exist in the eyes, ears, nervous system, and heart, where they have different functions, like maintaining balance and preventing damage.
- Vitiligo, a skin pigmentation disorder, is linked to various systemic disorders, highlighting that it can affect more than just the skin.
- The authors review the connections between vitiligo and other systemic diseases, emphasizing the diverse roles of melanocytes beyond pigmentation.
Use of Biologics in Private Practice: Nine Years of Lessons and Learning.
J Drugs Dermatol
March 2017
Over a decade ago, the FDA approved biologics for psoriasis, which changed how the disease is treated and, in most cases, has a significant positive impact on the lives of patients. Side effects primarily identified during the investigational and research phase led to the development of specific guidelines for treatment. The treatment guidelines have been amended to incorporate better understandings of side-effects over the years that the disease has been treated.
View Article and Find Full Text PDFA 70-year-old man was referred by his rheumatologist to our dermatology clinic for evaluation of dermatitis on his right arm that appeared 3 months earlier. The skin lesion was asymptomatic and the patient denied current systemic symptoms, including fever, chills, and joint pain; however, 10 months prior to this presentation he experienced arthritis in the left knee. At that time, Borrelia serology revealed positive IgG (6.
View Article and Find Full Text PDFBackground: Dysplastic nevi (DN) have been a matter of controversy since their initial description in 1978 because of differences in the clinical and histological terminology, and large studies on histological outcomes of excising moderate to severely DN have not previously been described.
Objective: To determine the clinical characteristics of DN and histologic outcomes of excised moderate and severe DN.
Methods: Retrospective chart review of patients with DN or Clark's nevi at the Dermatology Department at Rutgers-Robert Wood Johnson Medical School in Somerset, New Jersey, from January 2009 to June 2012.